Dementia Disease Trials including Alzheimer’s Disease (AD)

The following are ongoing Alzheimer’s Disease clinical trials in Canada:


Study to Evaluate Efficacy of ALZ-801 in APOE4/4 Early AD Subjects (APOLLOE4)


A Study of Donanemab (LY3002813) in Participants With Early Alzheimer’s Disease (The TRAILBLAZER-ALZ 2 Study)


A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer’s Disease (TRAILBLAZER-EXT)


A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer’s Disease (INVOKE-2)


Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer’s Disease (BUENA)


Open Label Extension of Phase 2b/3 Study ANAVEX2-73-AD-004 (ATTENTION-AD)


A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into the Cerebrospinal Fluid of Participants With Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)


A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205


Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer’s Disease (REFOCUS-ALZ)


A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy


Research Study Investigating Semaglutide in People With Early Alzheimer’s Disease (EVOKE)


A Research Study Investigating Semaglutide in People With Early Alzheimer’s Disease (EVOKE Plus)


Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)